Product Information
KEVZARA 200 MG/1.14 ML PEN INJ is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $2075.2968 per ML under NDC 00024592201. Its NADAC has been published 124 times since May 22, 2024.
Strength
200 mg/1.14mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00024592201
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SARILUMABApproval Type
Biologic (BLA)
FDA Application
BLA761037On Market Since
5/22/2017
Pharmacological Classes
Price Statistics
The NADAC for KEVZARA 200 MG/1.14 ML PEN INJ has been published 124 times since May 22, 2024, and over the history we have for it it has risen 12.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2075.2968 per ML |
|---|---|
| All-time high | $2082.1048 (Jun 10, 2026) |
| All-time low | $1845.7572 (Jul 17, 2024) |
| 52-week high | $2082.1048 |
| 52-week low | $1956.5839 |
| Median price | $1961.8673 |
| Average price | $1968.1324 |
| Largest weekly change | +6.0% (Jan 8, 2025) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sarilumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-6 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KEVZARA 200 MG/1.14 ML PEN INJ?
The current National Average Drug Acquisition Cost (NADAC) for KEVZARA 200 MG/1.14 ML PEN INJ, manufactured by Sanofi-Aventis U.S. LLC, is $2075.2968 per ML (NDC 00024592201), effective Sep 30, 2026.
How has the price of KEVZARA 200 MG/1.14 ML PEN INJ changed over time?
Over the history we have for it, the NADAC for KEVZARA 200 MG/1.14 ML PEN INJ has risen 12.0%. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for KEVZARA 200 MG/1.14 ML PEN INJ?
Since May 22, 2024, the NADAC for KEVZARA 200 MG/1.14 ML PEN INJ has ranged from a low of $1845.7572 (Jul 17, 2024) to a high of $2082.1048 (Jun 10, 2026), with a median of $1961.8673 per ML.
Are there cheaper alternatives to KEVZARA 200 MG/1.14 ML PEN INJ?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, KEVZARA 200 MG/1.14 ML SYRINGE, is $2068.0640 per ML — about 0% below KEVZARA 200 MG/1.14 ML PEN INJ.
Who manufactures KEVZARA 200 MG/1.14 ML PEN INJ?
KEVZARA 200 MG/1.14 ML PEN INJ (NDC 00024592201) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.